Literature DB >> 22166452

Parkinson's disease: molecular risk factors.

Edna Grünblatt1.   

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disorder second only to Alzheimer's disease. Diagnosis remains clinical, based on phenotypic patterns. In the last decade many attempts to develop early differential pre-clinical markers have been reported. In this presentation, the molecular risk factors that may link between the etiopathogenesis leading to PD and peripheral markers will be discussed. Genetic variation known to be involved in familial forms of PD will be shown to be linked to sporadic cases, as for example leucine-rich repeat kinase 2 (LRRK2) that was found to regulate microRNA-mediated translation regulation. In addition postmortem microarray findings of transcription alterations will be compared to the peripheral findings of mRNA profiles. Molecular processes involved in ubiquitination and proteasome, autophagy, mitochondrial dysfunction and the nicotinic and adenosine A2 protection will be discussed. The question of what time-point should be used measuring the different markers and the course of the disease considered, and the future possibilities in exploring these techniques will be debated.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22166452     DOI: 10.1016/S1353-8020(11)70016-5

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  8 in total

Review 1.  Rodent models and contemporary molecular techniques: notable feats yet incomplete explanations of Parkinson's disease pathogenesis.

Authors:  Sharawan Yadav; Anubhuti Dixit; Sonal Agrawal; Ashish Singh; Garima Srivastava; Anand Kumar Singh; Pramod Kumar Srivastava; Om Prakash; Mahendra Pratap Singh
Journal:  Mol Neurobiol       Date:  2012-06-27       Impact factor: 5.590

Review 2.  Aldehyde dehydrogenase (ALDH) in Alzheimer's and Parkinson's disease.

Authors:  Edna Grünblatt; Peter Riederer
Journal:  J Neural Transm (Vienna)       Date:  2014-10-09       Impact factor: 3.575

3.  Differential Alterations in Metabolism and Proteolysis-Related Proteins in Human Parkinson's Disease Substantia Nigra.

Authors:  Edna Grünblatt; Josefine Ruder; Camelia Maria Monoranu; Peter Riederer; Moussa Bh Youdim; Silvia A Mandel
Journal:  Neurotox Res       Date:  2017-12-07       Impact factor: 3.911

Review 4.  The roles of non-coding RNAs in Parkinson's disease.

Authors:  Maryam Majidinia; Aynaz Mihanfar; Reza Rahbarghazi; Alireza Nourazarian; BakiyeGoker Bagca; Çığır Biray Avci
Journal:  Mol Biol Rep       Date:  2016-08-05       Impact factor: 2.316

Review 5.  miRNAs as Circulating Biomarkers for Alzheimer's Disease and Parkinson's Disease.

Authors:  Gohar Mushtaq; Nigel H Greig; Firoz Anwar; Mazin A Zamzami; Hani Choudhry; Munvar M Shaik; Ian A Tamargo; Mohammad A Kamal
Journal:  Med Chem       Date:  2016       Impact factor: 2.745

Review 6.  Alcohol Consumption and Parkinson's Disease Risk: A Review of Recent Findings.

Authors:  Silvana S Bettiol; Tanith C Rose; Clarissa J Hughes; Lesley A Smith
Journal:  J Parkinsons Dis       Date:  2015       Impact factor: 5.568

7.  Pilot study: molecular risk factors for diagnosing sporadic Parkinson's disease based on gene expression in blood in MPTP-induced rhesus monkeys.

Authors:  Liangqin Shi; Chao Huang; Qihui Luo; Yu Xia; Heng Liu; Like Li; Wentao Liu; Wenjing Ma; Jing Fang; Li Tang; Wen Zeng; Zhengli Chen
Journal:  Oncotarget       Date:  2017-11-10

8.  Gastrodin protects dopaminergic neurons via insulin-like pathway in a Parkinson's disease model.

Authors:  Jinyuan Yan; Zhongshan Yang; Ninghui Zhao; Zhiwei Li; Xia Cao
Journal:  BMC Neurosci       Date:  2019-06-17       Impact factor: 3.288

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.